IgG to capsular polysaccharide (CPS) of Streptococcus pneumoniae is thought to provide the greatest degree of protection against pneumococcal disease. Serum obtained at hospital admission from 14 (27%) of 51 patients with bacteremic pneumococcal pneumonia and 11 (37%) of 30 with nonbacteremic pneumococcal pneumonia contained IgG to CPS of the infecting serotype; these percentages are similar to the prevalence of IgG to CPS in a control population. However, when compared with antibody from healthy adults, this IgG had far less capacity to opsonize the infecting pneumococcal serotype for phagocytosis in vitro by normal human polymorphonuclear leukocytes or to protect mice against experimental challenge. Failure to opsonize correlated closely with failure to protect mice, and each of these parameters correlated well with poor avidity for CPS. Future vaccine studies may need to examine the functional capacity of antibodies as a surrogate for infection, in addition to measuring their concentration in serum.
IgG to capsular polysaccharide (CPS) of Streptococcus pneumoniae is thought to provide the greatest degree of protection against pneumococcal disease. Serum obtained at hospital admission from 14 (27%) of 51 patients with bacteremic pneumococcal pneumonia and 11 (37%) of 30 with nonbacteremic pneumococcal pneumonia contained IgG to CPS of the infecting serotype; these percentages are similar to the prevalence of IgG to CPS in a control population. However, when compared with antibody from healthy adults, this IgG had far less capacity to opsonize the infecting pneumococcal serotype for phagocytosis in vitro by normal human polymorphonuclear leukocytes or to protect mice against experimental challenge. Failure to opsonize correlated closely with failure to protect mice, and each of these parameters correlated well with poor avidity for CPS. Future vaccine studies may need to examine the functional capacity of antibodies as a surrogate for infection, in addition to measuring their concentration in serum.
For more than a century, humoral immunity has been recognized as the principal mechanism of defense against infection by Streptococcus pneumoniae [1] [2] [3] . IgG to capsular polysaccharides (CPS) is thought to provide the greatest degree of protection, and pneumococcal vaccine is administered to stimulate such antibody. However, a protective level of IgG has not been determined and, in light of recent studies showing that some older persons may generate poorly functional antibody [4, 5] , it seems unlikely that such a level can be identified. It is not even certain whether, at the time of hospital admission, patients with pneumococcal pneumonia have antibody to the capsule of their infecting serotype. Use of a relatively insensitive agglutination technique in the preantibiotic era suggested that this antibody was not present [1] . In contrast, in the 1980s, the use of a relatively sensitive but nonspecific RIA [6] demonstrated levels of anticapsular antibody that were thought to be protective (1400 ng antibody N/mL) in nearly half of patients at hospital admission for pneumococcal pneumonia. This assay did not distinguish between nonprotective antibody to cell wall polysaccharide (CWPS) [7] and antibody to capsule; to our knowledge, such studies have not been repeated using the modern, sensitive yet specific ELISA [8, 9] .
We sought to determine whether, at the time of hospital admission, patients with pneumococcal pneumonia have antibody to the CPS of their infecting organism and, if they do, why this antibody is not protective. Our general method was to identify patients with pneumococcal pneumonia, retrieve the serum sample obtained from them at admission, serotype the infecting isolate, assay for antibody to the infecting CPS type by ELISA, and examine the functional activity in vitro and in vivo, if such antibody was present. We examined the in vitro activity by opsonization of an isolate of the same serotype for phagocytosis by human polymorphonuclear leukocytes (PMNL), and we examined the in vivo activity by the capacity to protect mice against challenge with this strain.
Methods
Subjects. Each day from 1 September 1996 through 31 March 1997 and from 1 September 1997 through 30 April 1999, one of the investigators reviewed bacterial culture results in the Microbiology Laboratory, Veterans Affairs Medical Center, Houston. Patients were initially considered for inclusion in this study if a culture of sputum or blood yielded S. pneumoniae. Patients were included (1) if they met case definitions (see below), (2) if у1 mL of serum that was obtained on the day of admission was available, and (3) if the infecting pneumococcal isolate was of a serotype contained in the 23-valent pneumococcal vaccine (the only types for which we regularly assay antibody). All sera were distributed to tubes in 0.5-mL aliquots. Sera and infecting bacterial isolates were stored at Ϫ70ЊC. Sera obtained on the day of admission are called "acute sera," and sera obtained 10 days to 12 weeks after the onset of pneumonia are called convalescent sera.
Bacteremic pneumococcal pneumonia. Patients with the diagnosis of bacteremic pneumococcal pneumonia had a clinical pre-sentation consistent with pneumonia (generally including у1 of the following: subjective fever, cough, sputum production, or pleuritic chest pain), radiographic confirmation of a pulmonary infiltrate, and у1 blood culture that yielded S. pneumoniae.
Nonbacteremic pneumococcal pneumonia. Criteria for diagnosing nonbacteremic pneumococcal pneumonia were stringent in order to exclude patients for whom the diagnosis might be questionable. Such patients had all or nearly all of the following: clinical presentation suggestive of pneumonia with cough, sputum production, subjective fever or chills (or both), physical findings of pneumonia, and a distinct infiltrate on plain chest radiography. Examination by microscope of a gram-stained sputum sample (reviewed by D.M.M.) in every case showed у20 white blood cells per epithelial cell, with large numbers of gram-positive cocci in pairs and chains and no (or rare) other bacterial forms; sputum culture yielding S. pneumoniae and no other likely bacterial pathogens; and у1 negative and no positive blood cultures results before antibiotic therapy was begun. Many of these patients also had chest pain, documented fever in the hospital, and an elevated peripheral white blood cell count with increased numbers of bands.
Colonized subjects. Colonized subjects were persons from whose sputum S. pneumoniae was grown but who had no symptoms, signs, or radiographic changes suggestive of acute bacterial infection, who received no treatment for pneumococcal infection, and who showed no deterioration in the hospital that might have been consistent with an untreated bacterial disease. Such persons usually had a sputum sample cultured during evaluation of relatively stable lung lesions, such as pulmonary fibrosis, emphysema, or malignancy.
Control sera. Sera from 3 groups of healthy adults (control, positive control, and negative control subjects) were used individually or pooled. The control subjects were 34 healthy middle-aged adults who had participated in studies of pneumococcal vaccination in our laboratory. Sera obtained from the participants before and 4 weeks after they received a 23-valent pneumococcal vaccine had been stored at Ϫ70ЊC. To determine the prevalence of IgG before and after vaccination, we assayed these sera for IgG to 5 common CPS (CPS 3, 4, 6B, 19F, and 23F). The positive reference serum pool was constituted by combining equal volumes of postvaccination sera from healthy control subjects. Positive control subjects were 5 persons selected from the above-mentioned 34 on the basis of having postvaccination IgG levels у5 mg/mL to the 5 serotypes under study. Negative control subjects were healthy adults who were chosen because pre-and postvaccination sera contained no detectable IgG to the 5 pneumococcal serotypes cited above [10] .
Serotyping. All pneumococcal isolates were typed, using procedures that are described in detail elsewhere [11] , with antisera obtained from Statens Seruminstitut (Copenhagen). Coagglutination with Staphylococcus aureus was used to amplify the effect of the antiserum [11] .
ELISA for antibody to CPS. Individual CPS (American Type Culture Collection, Manassas, VA) dissolved in PBS with 0.05% azide, 10-20 mg/mL, were incubated in wells of Immulon II plates (Dynatech, Chantilly, VA) for 5 h at 37ЊC and then incubated for 16 h at 4ЊC, as we have described elsewhere [12] . Before use, plates were blocked with PBS with 0.2% Tween 20 (PBST) for 1 h at 37ЊC and then washed 4 times with PBST. Sera were diluted 1:100 in PBS that contained 0.05% azide; isolated IgG suspensions from circulating immune complexes (CIC) were used undiluted. CWPS (10 mg/mL; Statens Seruminstitut) was added, and diluted sera and isolated IgG suspensions from CIC were incubated for 30 min at 4ЊC on a rocking platform, after which 2 3-fold dilutions were made from the already diluted, CWPS-adsorbed sera. Triplicate samples at each dilution were pipetted into wells coated with CPS and incubated at 37ЊC for 2 h, and wells were then washed 4 times with PBST.
IgG or CPS-reactive IgM was detected by the reaction of alkaline phosphatase-conjugated goat anti-human IgG or IgM and its substrate (Sigma, St. Louis). Each ELISA plate included 6 dilutions of a positive laboratory reference standard serum with a known concentration of IgG or IgM to a specific CPS based on the common reference serum 89-SF (provided by the Center for Biologics Evaluation and Research, Rockville, MD) as well as a negative laboratory reference serum that contained no IgG or IgM to the individual CPS under study [10] . Sera that yielded a result equal to or less than the negative reference serum were read as zero, although because of variation in the baseline and the asymptotic shape of the positive reference standard curve, a low level of IgG (generally !0.5 mg/mL) might, on occasion, appear to be present. Optical density was recorded by an automated reader (Dynatech).
After the antibody assays described in this study had been completed, we became aware of the possibility that adsorption with CPS from type 22F together with CWPS might remove crossreacting IgG more completely than adsorption with CWPS alone. Sera that contained antibody were studied again after adsorption in this fashion; measured levels of IgG declined by р30%, and in no case was a serum that was regarded as containing antibody to the CPS of the admitting strain converted to one that seemed to lack antibody.
Separation of immune complexes. To precipitate CIC [13] , we added 1 mL of serum to 1 mL of 12.5% polyethylene glycol in 0.1 M borate buffer (pH 8.4) and added 3 mL of distilled water to bring the volume to 5 mL. The resulting solution was maintained at 4ЊC for 90 min, after which the pellet was separated by centrifugation and washed three times with 2 mL of 2.5% polyethylene glycol in 0.1 M borate buffer. Antibody was dissociated by resuspending the precipitate in 1 mL of 0.1 M borate buffer (pH 10.4). IgG from the dissociated complexes was purified using 1-mL affinity columns (HiTrap protein A; Pharmacia Biotech, Uppsala, Sweden) according to the manufacturer's directions.
Flow cytometry assay of phagocytosis. Pneumococcal colonies were grown for 15 h at 37ЊC in 5% CO 2 on blood agar plates and then scraped from the surface of the plates and suspended in Hanks' balanced salt solution without Ca 2ϩ or Mg 2ϩ (HBSS), yielding ∼10 9 cfu/mL. To count colony-forming units, we serially diluted and plated an aliquot. The suspension was washed twice, incubated at 56ЊC for 30 min to inactivate autolysin, washed again, and resuspended in 0.1 M NaHCO 3 buffer (pH 9). Fluoroscein-isothiocyanate (FITC; 1 mg/mL; Sigma) was added, and the suspension was incubated on a shaking platform in the dark at 4ЊC for 18 h. FITClabeled bacteria were washed 5 times and resuspended in HBSS to yield 10 8 cfu/mL; these bacteria were dispensed to tubes wrapped in aluminum foil and stored at Ϫ20ЊC for use within 3-4 months.
PMNL were isolated from whole blood of healthy adults by sedimentation in Histopaque 1119 and 1077 (Sigma). Red blood cells were lysed by brief exposure to 0.2% saline, after which PMNL were resuspended in HBSS with 0.1% gelatin (GHBSS) to cells/ 6 5 ϫ 10 mL.
Bacteria were opsonized as follows. Each reaction mixture contained serum, which was diluted to yield 2 mg/mL IgG to the relevant serotype, cfu bacteria, and 6% complement-rich 6 5 ϫ 10 guinea pig serum in a final volume of 225 mL. If the IgG concentration of the original serum was below a level that can be diluted to 2 mg/mL in the final mixture, a lower concentration (but not у1 mg/mL) was used. This mix was incubated for 30 min in a vigorously shaking water bath at 37ЊC. The reaction was stopped by adding 1 mL of ice-cold HBSS. Opsonized bacteria were washed once and resuspended in 100 mL of GHBSS containing Ca 2ϩ and Mg 2ϩ . For the phagocytosis assay, flow cytometry was used to quantitate cell-associated bacteria by a modification of a previously reported method that included experiments showing that cellassociated bacteria were largely taken up by the phagocytic cells [14] . GHBSS (100 mL) with Ca 2ϩ and Mg 2ϩ and containing PMNL were added to the opsonized bacteria to yield a 5 5 ϫ 10 ratio of 10 bacteria to 1 PMNL. The bacteria-PMNL suspension was incubated for 30 min in a vigorously shaking water bath at 37ЊC. The reaction was stopped with 1 mL of ice-cold GHBSS, followed by a wash, and the pellet was resuspended in 400 mL of GHBSS. Fluorescein from surface-adherent bacteria was quenched by adding 100 mL of 0.1% trypan blue (pH 7.2) and incubating for 10 min at room temperature. The suspension was washed twice with 5 mL of GHBSS and resuspended in 350 mL of GHBSS with 1% paraformaldehyde (pH 7.35). Uptake of fluorescein-labeled pneumococci by PMNL was measured by flow cytometry (FACSII; Becton Dickinson, Sparks, MD).
Duplicate samples of 10,000 cells each were analyzed. PMNL were gated according to their characteristic light-scattering pattern. Log 10 fluorescein intensity (FI) was plotted against cell number. Total FI for each PMNL sample was calculated on the basis of the total number of labeled PMNL and the mean FI of each PMNL. Data are reported as the opsonic index, which is the total FI generated by patient serum divided by the total FI generated by the positive reference serum pool (expressed as a percentage). Opsonic index was related to functional activity by stratifying data on the basis of a cut-off opsonic index value of 50, such that indices !50 are considered as poorly functional.
Each phagocytosis experiment included 4 negative controls: (1) a negative laboratory reference serum that lacked IgG to the relevant CPS being studied, (2) a sample in which diluted serum was replaced with HBSS, (3) a sample in which both diluted serum and guinea pig serum were replaced with HBSS, and (4) a sample in which labeled bacteria were replaced with HBSS. These negative controls were included to ensure that (in the order they are listed) (1) phagocytosis was not due to immune components in serum other than specific IgG to CPS, (2) phagocytosis was not attributable to the effect of guinea pig serum alone, (3) serum IgG and complement were both needed for optimal phagocytosis, and (4) the fluorescein signal was from labeled bacteria. These controls consistently showed low-level activity: (no. 4 3), and above) ! (no. (no. index of 10. Whenever possible, sera 2) ! (no. 1) р opsonic from 1 patient in each group and 1 control subject were studied concurrently. Acute and convalescent sera were always studied concurrently.
Mouse protection. Outbred Swiss white mice, weighing 18-25 g, were housed at an ambient temperature of 22ЊC in a room that was lighted for 12 h each day. Sera were diluted in saline to yield a range of concentrations of anticapsular IgG, and 0.1-mL volumes were injected intraperitoneally into groups of 4-5 animals [15] . For each experiment, groups of mice received diluted acute serum and, if available, convalescent serum from у1 patients and the positive reference serum pool with equivalent concentrations of anticapsular IgG. Control animals received 0.1 mL of saline. Absorption of particulate or dissolved material from the peritoneal cavity is rapid and complete [16] . Forty-five minutes later, mice were injected intraperitoneally with 10 LD 50 of the relevant pneumococcal serotype, which was obtained by thawing a well-characterized frozen stock and serially diluting it in saline. cfu were verified by dilution and plating after injection. Mice were observed daily for 7 days, after which no deaths occurred. The protective index was defined as the number of mice that survived after receiving the highest dose of IgG from a patient serum divided by the number of mice that survived at the same dose of IgG from the positive reference serum pool expressed as a percentage.
In phagocytosis and mouse protection experiments, a representative isolate of the same serotype as the infecting one was used to insure uniformity of data. In addition, because we have not been able to construct a column that successfully purifies anticapsular antibody, we did not use isolated IgG to CPS; rather, in each experiment, whole serum was adjusted by dilution to achieve the desired concentration of anti-CPS IgG. As a result, the possible contribution of other antibodies to phagocytosis in vitro and/or to protection of mice after pneumococcal challenge can not be excluded. However, in our assay, the absence of anticapsular IgG results in the failure to opsonize for phagocytosis, as shown above, or to protect mice, factors which seems to argue against an important protective role for other antibodies.
Determination of avidity constant by inhibition ELISA. Sera were diluted to yield 0.3 mg/mL IgG to the relevant CPS, a concentration which gives a reading of ∼1 optical density unit by ELISA. Diluted sera were incubated with CWPS to remove crossreacting IgG. CPS was serially diluted to give concentrations ranging from 0.08 to 60 mg/mL and added to diluted sera; these mixtures were then incubated at 4ЊC on a rocking platform for 60 min. Diluted sera without CPS were studied to determine total free IgG. After this step, ELISA was done as described above except that serum incubation was limited to 1 h in order to minimize the disturbance of the solution-phase equilibrium, which may be caused by the binding of IgG to solid-phase CPS. Every ELISA plate included a laboratory standard with a known concentration of IgG to the relevant CPS.
IgG that was bound to CPS in solution was determined by subtracting free IgG, which was detected by ELISA (IgG bound to solid-phase CPS) from the total IgG as measured in sample without the inclusion of CPS. A Michaelis-Menten plot was constructed, with CPS (mg/mL) shown on the x-axis and bound IgG in solution (expressed in optical density units) on the y-axis. The association between anticapsular antibody and CPS substrate was determined by calculating the binding constant (Km) and the saturation rate at which antibody binds CPS (V max ), according to the equation , where V is the reaction rate and S is the Statistics. SAS software (version 6.12; SAS, Cary, NC) was used for x 2 and regression analyses. Analysis for continuous variables using Student's t test was performed with Excel software (version 5.0; Microsoft, Redmond, WA).
Results

Antibody to CPS.
Serum from the day of admission ("acute serum") was available from 100 patients: 51 with bacteremic pneumococcal pneumonia, 30 with nonbacteremic pneumococcal pneumonia, and 19 who were colonized with S. pneumoniae. Most patients lacked detectable IgG to CPS of the same type as their infecting pneumococcus; only 14 (27%) of 51 bacteremic and 11 (37%) of 30 nonbacteremic patients had such IgG at the time of admission, as did 8 (42%) of 19 who were colonized (table 1) . We determined the prevalence of IgG to 5 common pneumococcal CPS (3, 4, 6B, 19F, and 23F) in sera from 34 healthy, age-matched control subjects. Of 170 possible reactions ( ), 48 (28%) were positive, a percentage 5 ϫ 34 similar to that observed in our patients at the time they were admitted with pneumococcal infection or colonization ( , P = .5 comparison). 2 
ϫ 4x
A second serum sample was obtained 10 days to 12 weeks after admission ("convalescent serum") from 30 subjects (13 bacteremic, 13 nonbacteremic, and 4 colonized). At this point, 19 (63%) of the 30 subjects had IgG to CPS of the infecting serotype (table 1); this proportion was similar to the 61% of reactions that were positive in control subjects after pneumococcal vaccination.
At 0.9 mg/mL, the geometric mean IgG was lowest in acute sera of bacteremic patients, compared with 1.2 and 1.5 mg/mL in nonbacteremic and colonized subjects, respectively (differences not significant). The geometric mean in convalescent sera increased ∼3-fold in bacteremic patients (from 0.9 to 2.5 mg/ mL, ) and nonbacteremic patients (from 1.2 to 3.8 mg/ P = .34 mL, ), while remaining unchanged in colonized subjects P = .05 (1.5 vs. 1.5 mg/mL, ). When geometric mean IgG in acute P = .39 and convalescent sera was calculated using only data from paired sera, similar results were obtained ( figure 1) .
Detection of antibody in CIC. CIC were isolated and dissociated from a convenience sample of 34 acute sera (18 patients with bacteremic pneumonia, 9 with nonbacteremic pneumonia, and 7 who were colonized). IgG to CPS of the infecting strain was found by ELISA in CIC from 2 serum samples (1 from a patient with bacteremic pneumonia and the other from a colonized subject). These results (table 1) suggest that the failure to detect IgG in serum signifies a true absence of such antibody, although they do not exclude the possibility that IgG is bound to pneumococci in the lungs without release of complexes to the circulation.
Opsonophagocytosis. Pilot studies showed linear dose-response curves relating the uptake of pneumococci to opsonizing concentrations of IgG from 1 to 10 mg/mL (obtained by dilution of individual sera) or to bacteria:PMNL ratios of 10:1 to 100:1 (using bacteria of the same serotype as the infecting organism). Accordingly, in subsequent experiments, opsonization was carried out with individual patient sera and the positive reference serum diluted to yield a final concentration of 2 mg/ mL anticapsular IgG, with the exception of sera that contained !2 mg/mL of anticapsular IgG, as explained in Methods. Phagocytosis was studied at a ratio of 10 bacteria to 1 PMNL.
Results, reported as opsonic indices (defined in Methods), showed that serum antibody present at admission for pneumococcal pneumonia was poorly opsonic for the infecting serotype compared with that from colonized subjects, the positive reference serum pool, or individual positive control sera (stud- Figure 2 . Geometric means of opsonic indices (defined in Methods) are shown for study subjects. Pneumonia patients (bacteremic and nonbacteremic) and healthy control subjects lacked measurable IgG to the capsular polysaccharide. Ⅺ, Acute serum; Ⅵ, convalescent serum (defined in Methods). ied only for serotypes 4 and 23F). The geometric mean opsonic index for all acute sera studied was 16.7 for bacteremic and 13.4 for nonbacteremic pneumococcal pneumonia patients, compared with 58.0 for colonized subjects, 100 (by definition) for the positive reference serum pool, and 117 for positive control subjects (figure 2). The differences are significant for bacteremic or nonbacteremic acute sera versus positive control sera ( ) but not for colonized subjects ( ). P ! .005 P = .45 The finding that the geometric mean opsonic index for individual positive control sera closely resembled that of the positive reference pool serum validates the averaging effect that resulted from pooling sera. The geometric mean opsonic index was 6 for acute sera from 10 pneumonia patients who lacked antibody to their infecting serotype (serotypes 4 and 23F were used for these experiments), and the index was 14 for acute sera from 5 healthy adults (negative controls) who had no detectable IgG to CPS 4 and 23F. These indices were significantly lower than those for positive control subjects ( ; figure P ! .001 2), and confirm that sera lacking antibody to CPS failed to opsonize for phagocytosis In convalescence, opsonization by serum from bacteremic patients remained low (geometric mean opsonic index, 21.3), while the geometric mean opsonic index from nonbacteremic patients rose to 118.2, a significant increase over that for acute sera from these same subjects ( ), and exceeded values P ! .005 for convalescent sera of bacteremic patients ( ). The geo-P = .12 metric mean opsonic index in follow-up sera from colonized subjects rose to 84.8, approaching that for the positive reference serum pool (figure 2).
When results were stratified into low (!50) or normal (у50) opsonic indices, acute sera from 11 of 12 bacteremic, 9 of 10 nonbacteremic patients, and 3 of 5 colonized subjects had low functional activity (table 2) . Among the control subjects that we studied, 10 of 10 IgG-negative patients and 5 of 5 negative control subjects had minimal opsonic activity, whereas 10 of 10 individual positive control subjects, selected because they had IgG to CPS 4 and 23F, had normal opsonic activity. The differences in the proportions of persons whose sera had low or normal functional activity are significant when comparing positive control subjects and bacteremic or nonbacteremic patients or colonized subjects ( for each comparison). An-P ! .05 tibody detected in convalescent sera was likely to be more functional, showing an opsonic index у50 in 3 of 6 bacteremic, 7 of 8 nonbacteremic, and 2 of 2 colonized subjects (table 2). The increase in functional activity from 1 of 10 acute sera to 7 of 8 convalescent sera in nonbacteremic patients was significant ( ) .
Mouse protection. The capacity of anticapsular antibody in patient sera to protect mice against challenge with mousevirulent serotypes (types 3, 4, and 8 in this study) was then examined in vivo. In each experiment, patient sera and the positive reference serum pool were adjusted by dilution in saline to deliver a range of desired doses of IgG that varied with the serotype. In 2 separate experiments (figure 3), 11 ng of IgG to type 4 CPS from serum of a healthy adult nearly completely protected mice against challenge with S. pneumoniae type 4, and 33 ng of IgG was fully protective. In contrast, 33 ng of IgG from acute serum of a patient with type 4 bacteremic infection protected only 2 of 10 mice. Figure 4 shows data from an experiment in which 150 ng of IgG to CPS type 3 from acute sera for 2 bacteremic patients with type 3 infection (the highest dose that could be administered in 0.1 mL of undiluted serum) provided no protection against type 3 challenge. In contrast, lower amounts of IgG from the positive reference serum pool or from a nonbacteremic patient's acute or convalescent serum were partially protective. In this experiment, the positive reference serum pool was most protective, followed by the convalescent serum of the nonbacteremic patient and finally the acute serum of the same nonbacteremic patient. All experiments were repeated one or more times, limited in some instances by the amount of serum available. Similar results were obtained in other experiments. Statistical analyses were not performed on the protective index data because of the few data points for each category.
Correlation of opsonic and protective indices. Passive protection against lethal challenge correlated well with a high se- Correlation of antibody avidity and functional capacity. Antibody avidity as measured in vitro by an inhibition ELISA assay generally correlated well with functional activity as measured in vitro and in vivo. Sera that opsonized pneumococci well for phagocytosis or protected mice against experimental challenge (or both) had high-avidity anticapsular IgG, whereas those that did not opsonize and/or protect generally had lowavidity IgG. For S. pneumoniae serotype 3, which was associated with the highest number of patient sera containing IgG, correlation plots between antibody avidity constant and serum opsonic index, serum opsonic index and serum protective index, or antibody avidity constant and serum protective index show high correlations ( , ; , ; , r = .90 P ! .01 r = .93 P ! .005 r = .72 , respectively; figure 6). For only 2 sera in this study, in P ! .1 vitro phagocytosis did not correlate well with mouse protection. Both were from nonbacteremic patients with S. pneumoniae type 4 infection, and in both instances the serum protected mice but did not stimulate phagocytosis in vitro. One of these serum samples was available for avidity testing and was found to exhibit good avidity in vitro; the other sample was depleted during mouse protection studies, before avidity testing was done.
IgM levels. To determine the potential contribution of IgM to these results, we studied acute and convalescent sera from all subjects who were infected by or colonized with S. pneumoniae types 3 or 4. In the acute sera, 7 had IgG to the relevant serotype, and of them, 2 had IgM. One of these subjects was bacteremic, and the serum did not opsonize; the other subject was colonized and his serum showed opsonic activity. Of 8 without IgG, none had IgM. Of 8 patients from whom convalescent serum could be obtained, 1 each who had or did not have IgG also had IgM. One of these was bacteremic, and the other was nonbacteremic; neither serum opsonized the infecting organism. These results suggested that IgM contributed imperceptibly to the observed results.
Discussion
Pneumococcal pneumonia remains a common and serious medical problem, especially among elderly persons and people with underlying diseases [1, [17] [18] [19] . Despite appropriate antibiotic therapy, mortality from bacteremic pneumococcal pneumonia in hospitalized patients approaches 25% [17] [18] [19] , and there is fear that the rates of complications and death may increase with increasing resistance of S. pneumoniae to commonly available antibiotics. These factors have helped to rekindle interest in immunity to pneumococcal disease.
Throughout the past century, investigations of antipneumococcal immunity focused on antibody to CPS [1] [2] [3] ; however, in the past decade, research efforts have broadened to include a possible role for antibody to other surface constituents as well [20] [21] [22] [23] . Advances in methodology, first with the application of RIA [6] and later of ELISA [8, 9] , made it possible to quantitate antibody, whether acquired naturally or after administration of pneumococcal vaccine.
The observation that elderly persons and people with underlying diseases remain susceptible to pneumococcal disease even after vaccination [24, 25] led to the hypothesis that antibody levels in such populations were not as high or that the antibody did not function as well. An early study from our laboratory [26] showed that after vaccination, older men with chronic lung disease have lower levels of antibody than do healthy young adults. Sankilampi et al. [27] and Musher et al. [28] reported that the responses of very healthy elderly adults to pneumococcal vaccine are similar to or, in the case of certain polysaccharides, slightly lower than the responses of younger persons. Older adults who are not preselected for excellent health and vigor and who may have a variety of medical conditions associated with aging have lower postvaccination levels of IgG than do younger adults [4, 5] . More important, such persons may generate antibody that is poorly functional, as shown in vitro by poor opsonization for phagocytosis by tissuecultured cells and in vivo by reduced protection of mice against pneumococcal challenge [4, 5] .
By focusing on patients who actually have pneumococcal pneumonia, the present study enables us to examine more directly the degree to which preexisting antibody to the CPS of an infecting organism might protect against the development of infection. We found that at the time of admission to the hospital, most patients with pneumococcal pneumonia lack antibody to the CPS of their infecting serotype. When less sensitive techniques were used in the preantibiotic era, antibody was said to be absent at the time pneumonia is diagnosed; in contrast, we found that about one-third of patients have such antibody. Of interest, the prevalence of antibody in our patients was about the same as it is in the population at large [12] . Of even greater interest was the finding that anti-CPS IgG present at admission had diminished functional activity. Unlike sera from healthy age-matched adults, acute sera from patients, when adjusted by dilution to yield a fixed amount of IgG to CPS, failed to opsonize the infecting pneumococcal serotype effectively in vitro in nearly every instance.
Most pneumococcal types are not virulent for mice (virulence defined as an LD of !10 5 cfu/mL). Using strains of S. pneumoniae types 3, 4, and 8 that were isolated from patients and are virulent for mice, we found that serum containing anti-CPS IgG failed to protect mice against challenge in vivo. Results of an in vitro test of avidity suggested that the nonprotective antibody fails to bind CPS avidly. Taken together, these results suggest that patients are prone to pneumococcal infection either because they lack IgG to CPS or because, if such antibody is present, it functions poorly.
In general, our patients exhibited increases in IgG to typespecific CPS after infection. The proportion of subjects with IgG to CPS of their infecting serotype increased from about one-third to about two-thirds, again similar to the proportion of normal subjects who developed antibody after pneumococcal vaccination. Antibody produced in response to infection was more likely to be functional, at least in patients who did not have bacteremia. Of the small sample of subjects whose convalescent serum was studied, 88% of nonbacteremic patients and 50% of bacteremic patients had functional antibody.
Generation of poorly functional antibody is not exclusive to older, diseased individuals. Nahm et al. [29] have shown that pneumococcal vaccination stimulates the appearance of IgG that is cross-reactive (i.e., reactive with related, nonvaccine serotypes) and that such cross-reactive IgG has less opsonic activity than homologous IgG. Usinger and Lucas [30] showed that because of the polymorphic nature of IgG 2 responses to CPS, healthy young adults who receive pneumococcal vaccine generate IgG with a range of avidity for the polysaccharide antigen. Several important problems remain to be addressed, including whether persons who generate poorly functional antibody to one polysaccharide do so to all polysaccharides, at what point and how (at a molecular level) the change from functional to nonfunctional antibody takes place, and whether presentation of antigen in a different form (e.g., as a protein conjugate) will stimulate production of better functioning antibody.
The results of the present study provide further insights into the nature of immunity to pneumococcal infection. In an early study, Musher et al. [7] reported a direct relation between the IgG level measured by ELISA and opsonization of pneumococci or protection of experimental animals. In addition, Vidarsson et al. [31] showed a high degree of correlation between the concentration of IgG to CPS and opsonizing capacity; the findings of both these reports were based on serum from healthy young adults. Usinger and Lucas [30] show good correlation Figure 6 . A, Relation between avidity constant of IgG and opsonic index (defined in Methods) of sera studied for Streptococcus pneumoniae type 3. B, Relation between opsonic and protective indices of sera studied for the same serotype. C, Relation between avidity constant of IgG and protective index of sera studied for the same serotype.
between avidity and opsonizing activity and between opsonizing activity and mouse protection. If serum from sick or elderly adults had been used in any of these studies, greater discrepancies might have been noted [26] . Of interest, IgG from patients with severe underlying disease was not as likely as that from normal subjects to opsonize pneumococci. It should now be clear why a protective level of IgG has not been determined and why antibody level can not serve as a surrogate for immunity: the degree of immunity may vary greatly, depending upon the functional activity of the antibody, and the population most in need of vaccine may generate antibody that is measured by ELISA but is poorly functional. Our findings underscore the importance of using functional assays, rather than simply measuring IgG levels by ELISA, for studying and comparing polysaccharide vaccines.
On the basis of the pilot study of Yee et al. [32] , we studied patients with pneumococcal pneumonia, showing that those with bacteremic pneumonia have an increased risk of homozygosity for the R131 allele of the FCgRIIA surface receptor of PMNL [33] . R131 interacts poorly with Fc of IgG 2 , the IgG subclass that includes nearly all IgG to CPS, in contrast to the H131 allelic form, which avidly binds Fc of IgG 2 [34] . Rodriguez et al. [35] found that cultured phagocytic cells transfected with the gene product that encodes H131 ingest opsonized pneumococci more readily than those transfected with the gene for R131. Accordingly, we sought, in the patients included in the present study, to determine whether there was an association between homozygosity for R131 and the presence of IgG to the infecting capsular serotype. Patients who had antibody to the infecting serotype were no more likely to be homozygous for the R131 allele than were patients who had no antibody. Only 2 bacteremic patients had functional antibody to the infecting serotype at admission, and the FCgRIIA genotype was determined in only 1 of them; this patient was homozygous for R131. Sanders et al. [36] showed that children with the R131 allele may also have reduced IgG 2 responses to pneumococcal vaccine, a finding of further interest in light of our previous and present studies.
Ten patients in this series had received 23-valent pneumococcal vaccine; IgG was detected in acute serum from only 1 of these patients. The absence of antibody in the remaining 9 patients might be consistent with genetic incapacity to respond to a polysaccharide [37] , poor response due to age or underlying disease [4, 5] , or rapid loss of antibody after an initial response, as suggested by Shapiro et al. [25] . Some researchers [2, 38] have proposed that pneumococcal vaccination protects against bacteremia but not against pneumonia. This concept does not seem to be supported by an understanding of the pathophysiology of the disease because, with inflammation, plasma pours into alveoli, providing a milieu that is not so different from the blood stream. By demonstrating similar rates of antibody presence and lack of function in bacteremic and nonbacteremic subjects, our study further opposes that hypothesis.
We investigated the possibility that anticapsular IgG is not detected in most sera because it is bound in CIC. Such complexes were identified in only 2 of 34 sera examined. Large amounts of CPS can be found in the serum of patients who are hospitalized with pneumococcal pneumonia, and the levels remain high for some time [39] ; nevertheless, in most cases, anticapsular IgG also becomes detectable by 5-8 days after the onset of pneumonia and persists for months to years. Although patients with bacteremic or nonbacteremic pneumococcal pneumonia have been found to have elevated levels of CIC [39] [40] [41] , it has not been shown that these complexes contain IgG to CPS of the infecting serotype. Our study did not exclude the possibility that IgG is bound to capsular material in tissues and does not spill into the circulation.
